Glioma targeting and blood-brain barrier penetration bydual-targeting doxorubincin liposomes

Biomaterials

Volumn 34, Issue 22, 2013, Pages 5628-5639

  Gao, Jian Qing ^a   Lv, Qing ^a,b   Li, Li Ming ^a   Tang, Xin Jiang ^a   Li, Fan Zhu ^b   Hu, Yu Lan ^a   Han, Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Blood brain barrier; Dual targeting; Folate; Glioma; Liposome; Transferrin

Indexed keywords

BLOOD-BRAIN BARRIER; DUAL-TARGETING; FOLATE; GLIOMA; TRANSFERRIN;

BLOOD; CHEMOTHERAPY; LIPOSOMES;

TUMORS;

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DOXORUBICIN; FOLIC ACID; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; TRANSFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PENETRATION; DRUG TARGETING; GLIOMA; NICK END LABELING; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FOLIC ACID; GLIOMA; HUMANS; LIPOSOMES; MALE; MICE; PERMEABILITY; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; TRANSFERRIN;

EID: 84877623397     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.097     Document Type: Article

References (39)

1. Colman H., Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 2008, 65:877-883.
2. Black P.M. Brain tumor. Part 2. NEngl J Med 1991, 324:1555-1564.
3. Silbergeld D.L., Chicoine M.R. Isolation and characterization of human malignant glioma cells from histologically normal brain. JNeurosurg 1997, 86:525-531.
4. Dhanikula R.S., Argaw A., Bouchard J.F., Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008, 5:105-116.
5. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000, 57:679-686.
6. Juliano R.L., Ling V. Asurface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
7. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989, 86:695-698.
8. Ohnishi T., Tamai I., Sakanaka K., Sakata A., Yamashima T., Yamashita J., et al. Invivo and invitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995, 49:1541-1544.
9. Li X., Ding L., Xu Y., Wang Y., Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 2009, 373:116-123.
10. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93:14164-14169.
11. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. JDrug Target 2002, 10:317-325.
12. Fenart L., Buee-Scherrer V., Descamps L., Duhem C., Poullain M.G., Cecchelli R., et al. Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an invitro model of the blood-brain barrier. Pharm Res 1998, 15:993-1000.
13. Rousselle C., Smirnova M., Clair P., Lefauconnier J.M., Chavanieu A., Calas B., et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. JPharmacol Exp Ther 2001, 296:124-131.
14. Smith M.W., Gumbleton M. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. JDrug Target 2006, 14:191-214.
15. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312:162-163.
16. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
17. Park E.K., Lee S.B., Lee Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26:1053-1061.
18. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: invitro studies. Bioconjug Chem 1999, 10:289-298.
19. Ho J.A., Hung C.H., Wu L.C., Liao M.Y. Folic acid-anchored PEGgylated phospholipid bioconjugate and its application in a liposomal immunodiagnostic assay for folic acid. Anal Chem 2009, 81:5671-5677.
20. Saul J.M., Annapragada A., Natarajan J.V., Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor invitro. JControl Release 2003, 92:49-67.
21. Anabousi S., Bakowsky U., Schneider M., Huwer H., Lehr C.M., Ehrhardt C. Invitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006, 29:367-374.
22. Dipali S.R., Kulkarni S.B., Betageri G.V. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. JPharm Pharmacol 1996, 48:1112-1115.
23. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85:1987-1997.
24. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. JPharmacol Exp Ther 2001, 299:483-493.
25. Zhang Z., McGoron A.J., Crumpler E.T., Li C.Z. Co-culture based blood-brain barrier invitro model, a tissue engineering approach using immortalized cell lines for drug transport study. Appl Biochem Biotechnol 2011, 163:278-295.
26. Du J., Lu W.L., Ying X., Liu Y., Du P., Tian W., et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009, 6:905-917.
27. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
28. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. JControl Release 2010, 141:183-192.
29. Omidi Y., Campbell L., Barar J., Connell D., Akhtar S., Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an invitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003, 990:95-112.
30. Langner M., Kral T.E. Liposome-based drug delivery systems. Pol J Pharmacol 1999, 51:211-222.
31. Omori N., Maruyama K., Jin G., Li F., Wang S.J., Hamakawa Y., et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 2003, 25:275-279.
32. Soni V., Kohli D.V., Jain S.K. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. JDrug Target 2005, 13:245-250.
33. Suresh Reddy J., Venkateswarlu V., Koning G.A. Radioprotective effect of transferrin targeted citicoline liposomes. JDrug Target 2006, 14:13-19.
34. Zhao X.B., Lee R.J. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev 2004, 56:1193-1204.
35. Kamaly N., Kalber T., Thanou M., Bell J.D., Miller A.D. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug Chem 2009, 20:648-655.
36. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. Invivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003, 9:6551-6559.
37. Buzdar A.U., Marcus C., Smith T.L., Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985, 55:2761-2765.
38. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
39. Zhang P., Hu L., Yin Q., Feng L., Li Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol Pharm 2012, 9:1590-1598.